FRα: Novel Assessment for Targeted Treatment of Ovarian Carcinoma
MyWES®
The MyWES® test utilizes Whole Exome Sequencing (WES) to conduct a comprehensive analysis of more than 20,000 genes for the identification and diagnosis of genetic disorders.
Microsatellite Instability (MSI)
This test aids in selecting the most suitable treatment and facilitates individualized cancer therapy. Microsatellite instability (MSI) is predominantly observed in colorectal cancer and endometrial carcinoma. MSI has also been identified in cervical cancer, gastric cancer, glioblastoma, melanoma, ovarian cancer, and prostate cancer.
